Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US05370A1088
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG00FQ7LXW1
RNAM
Avidity Biosciences, Inc.
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: - · THEMEFOLIO: $HLTH
NAME
Avidity Biosciences, Inc.
ISIN
US05370A1088
TICKER
RNAM
MIC
XNAS
REUTERS
RNA.OQ
BLOOMBERG
RNAM US
Do., 03.10.2024       Avidity Biosciences
US05370A1088

SAN DIEGO, Oct. 3, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the U.S. Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (d...
Zur Nachricht
Avidity Biosciences
Charts & Research Termsheets Terminal
Permalink
Mi., 25.09.2024       Avidity Biosciences
US05370A1088

SAN DIEGO, Sept. 25, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating in the following upcoming conference:...
Zur Nachricht
Avidity Biosciences
Charts & Research Termsheets Terminal
Permalink
Mo., 23.09.2024       Avidity Biosciences
US05370A1088

SAN DIEGO, Sept. 23, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on September 20, 2024, the Human Capital Management Committee of Avidity's Board of Directors granted non-qu...
Zur Nachricht
Avidity Biosciences
Charts & Research Termsheets Terminal
Permalink
Do., 05.09.2024       Avidity Biosciences
US05370A1088

Avidity supports World Duchenne Awareness Day, International Myotonic Dystrophy Awareness Day, FSHD Society Walk & Roll to Cure FSHD and Global Genes Week in RARE Avidity reported groundbreaking data in all three clinical programs addressing rare muscular dystrophies: myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FS...
Zur Nachricht
Avidity Biosciences
Charts & Research Termsheets Terminal
Permalink
Mi., 28.08.2024       Avidity Biosciences
US05370A1088

SAN DIEGO, Aug. 28, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating in the following upcoming conferences:...
Zur Nachricht
Avidity Biosciences
Charts & Research Termsheets Terminal
Permalink
Mi., 21.08.2024       Avidity Biosciences
US05370A1088

SAN DIEGO, Aug. 21, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on August 20, 2024, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualif...
Zur Nachricht
Avidity Biosciences
Charts & Research Termsheets Terminal
Permalink
Mo., 19.08.2024       Avidity Biosciences
US05370A1088

SAN DIEGO, Aug. 19, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that it has closed its previously announced underwritten public offering of 8,418,000 shares of its common stock,...
Zur Nachricht
Avidity Biosciences
Charts & Research Termsheets Terminal
Permalink
Do., 15.08.2024       Avidity Biosciences
US05370A1088

SAN DIEGO, Aug. 14, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the pricing of its upsized underwritten public offering of 7,320,000 shares of its common stock at a price to the...
Zur Nachricht
Avidity Biosciences
Charts & Research Termsheets Terminal
Permalink
Di., 13.08.2024       Avidity Biosciences
US05370A1088

SAN DIEGO, Aug. 13, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that it intends to offer and sell, subject to market and other conditions, $250.0 million of shares of its common...
Zur Nachricht
Avidity Biosciences
Charts & Research Termsheets Terminal
Permalink
Fr., 09.08.2024       Avidity Biosciences
US05370A1088

Avidity reports positive del-zota (AOC 1044) data; demonstrated 25% increase in dystrophin production and reduction of creatine kinase levels to near normal in people living with DMD44 in Phase 1/2 EXPLORE44™ trial Initiated global Phase 3 HARBOR™ trial and began administration of del-desiran in people living with DM1; del-desiran received FDA B...
Zur Nachricht
Avidity Biosciences
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Fr., 09.08.2024       Avidity Biosciences
US05370A1088

Delpacibart zotadirsen (AOC 1044) delivered unsurpassed muscle concentrations of PMO of 200 nM after three doses of 5 mg/kg Statistically significant 37% increase in exon 44 skipping and up to 66% skipping with delpacibart zotadirsen 5 mg/kg at four months Statistically significant increase of 25% of normal in dystrophin production and restored...
Zur Nachricht
Avidity Biosciences
Charts & Research Termsheets Terminal
Permalink
Fr., 14.04.2023       Avidity Biosciences
US05370A1088

New York, New York--(Newsfile Corp. - April 14, 2023) - Pomerantz LLP is investigating claims on behalf of investors of Avidity Biosciences, Inc. ("Avidity" or the "Company") (NASDAQ: RNA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Avidity and...
Zur Nachricht
Avidity Biosciences
Charts & Research Termsheets Terminal
Permalink
So., 16.10.2022       Avidity Biosciences
US05370A1088

New York, New York--(Newsfile Corp. - October 16, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Avidity Biosciences, Inc. (NASDAQ: RNA) ("Avidity" or the "Company"). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Avidity a...
Zur Nachricht
Avidity Biosciences
Charts & Research Termsheets Terminal
Permalink
Sa., 08.10.2022       Avidity Biosciences
US05370A1088

New York, New York--(Newsfile Corp. - October 8, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Avidity Biosciences, Inc. ("Avidity" or the "Company") (NASDAQ: RNA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Avidity and...
Zur Nachricht
Avidity Biosciences
Charts & Research Termsheets Terminal
Permalink
Do., 29.09.2022       Avidity Biosciences
US05370A1088

Atlanta, Georgia--(Newsfile Corp. - September 29, 2022) - Holzer & Holzer, LLC is investigating whether Avidity Biosciences, Inc. ("Avidity" or the "Company") (NASDAQ: RNA) complied with federal securities laws. On September 27, 2022, Avidity announced that the U.S. Food and Drug Administration has placed a partial clinical hold on new...
Zur Nachricht
Avidity Biosciences
Charts & Research Termsheets Terminal
Permalink